210 related articles for article (PubMed ID: 23828145)
1. Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03).
Tanaka S; Miyazaki T; Uemura Y; Kuroda T; Miyakawa N; Nakamura T; Fukunaga M; Ohashi Y; Ohta H; Mori S; Hagino H; Hosoi T; Sugimoto T; Itoi E; Orimo H; Shiraki M
J Bone Miner Metab; 2014 May; 32(3):298-304. PubMed ID: 23828145
[TBL] [Abstract][Full Text] [Related]
2. Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis.
Kasukawa Y; Miyakoshi N; Ebina T; Aizawa T; Hongo M; Nozaka K; Ishikawa Y; Saito H; Chida S; Shimada Y
J Bone Miner Metab; 2014 May; 32(3):290-7. PubMed ID: 23846118
[TBL] [Abstract][Full Text] [Related]
3. Comparison of concurrent treatment with vitamin K
Tanaka S; Miyazaki T; Uemura Y; Miyakawa N; Gorai I; Nakamura T; Fukunaga M; Ohashi Y; Ohta H; Mori S; Hagino H; Hosoi T; Sugimoto T; Itoi E; Orimo H; Shiraki M
J Bone Miner Metab; 2017 Jul; 35(4):385-395. PubMed ID: 27484436
[TBL] [Abstract][Full Text] [Related]
4. Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.
Ringe JD; Farahmand P; Faber H; Dorst A
Rheumatol Int; 2009 Jan; 29(3):311-5. PubMed ID: 18762944
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.
Ringe JD; Faber H; Farahmand P; Dorst A
Rheumatol Int; 2006 Mar; 26(5):427-31. PubMed ID: 16001181
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
7. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
Hadji P; Zanchetta JR; Russo L; Recknor CP; Saag KG; McKiernan FE; Silverman SL; Alam J; Burge RT; Krege JH; Lakshmanan MC; Masica DN; Mitlak BH; Stock JL
Osteoporos Int; 2012 Aug; 23(8):2141-50. PubMed ID: 22159672
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effect of pretreatment and treatment continuation with risedronate and vitamin K2 on cancellous bone loss after ovariectomy in rats: a bone histomorphometry study.
Iwamoto J; Takeda T; Sato Y; Shen CL; Yeh JK
J Nutr Sci Vitaminol (Tokyo); 2006 Oct; 52(5):307-15. PubMed ID: 17190100
[TBL] [Abstract][Full Text] [Related]
9. The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial.
Sato Y; Honda Y; Umeno K; Hayashida N; Iwamoto J; Takeda T; Matsumoto H
Kurume Med J; 2011; 57(4):117-24. PubMed ID: 21778673
[TBL] [Abstract][Full Text] [Related]
10. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Reid DM; Devogelaer JP; Saag K; Roux C; Lau CS; Reginster JY; Papanastasiou P; Ferreira A; Hartl F; Fashola T; Mesenbrink P; Sambrook PN;
Lancet; 2009 Apr; 373(9671):1253-63. PubMed ID: 19362675
[TBL] [Abstract][Full Text] [Related]
12. Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Cranney A; Waldegger L; Zytaruk N; Shea B; Weaver B; Papaioannou A; Robinson V; Wells G; Tugwell P; Adachi JD; Guyatt G
Cochrane Database Syst Rev; 2003; (4):CD004523. PubMed ID: 14584020
[TBL] [Abstract][Full Text] [Related]
13. Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.
Roux C; Goldstein JL; Zhou X; Klemes A; Lindsay R
Osteoporos Int; 2012 Jan; 23(1):277-84. PubMed ID: 21365461
[TBL] [Abstract][Full Text] [Related]
14. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
15. Role of vitamin K2 in the treatment of postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Drug Saf; 2006 Jan; 1(1):87-97. PubMed ID: 18690918
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.
Hagino H; Kishimoto H; Ohishi H; Horii S; Nakamura T
Bone; 2014 Feb; 59():44-52. PubMed ID: 24184313
[TBL] [Abstract][Full Text] [Related]
17. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
Wallach S; Cohen S; Reid DM; Hughes RA; Hosking DJ; Laan RF; Doherty SM; Maricic M; Rosen C; Brown J; Barton I; Chines AA
Calcif Tissue Int; 2000 Oct; 67(4):277-85. PubMed ID: 11000340
[TBL] [Abstract][Full Text] [Related]
18. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
[TBL] [Abstract][Full Text] [Related]
19. Response of serum carboxylated and undercarboxylated osteocalcin to risedronate monotherapy and combined therapy with vitamin K(2) in corticosteroid-treated patients: a pilot study.
Hozuki T; Imai T; Tsuda E; Matsumura A; Yamamoto D; Toyoshima T; Suzuki S; Yamauchi R; Hayashi T; Hisahara S; Shimohama S
Intern Med; 2010; 49(5):371-6. PubMed ID: 20190467
[TBL] [Abstract][Full Text] [Related]
20. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
